TABLE 2

Clinical, hormonal, and metabolic features of women with PCOS (n = 21) before and after metformin treatment

VariableBefore metforminAfter metforminSignificance
Age (years)28 (26.5–31.5)28 (27.5–32.5)NS
BMI (kg/m2)32.8 (29.8–36.5)31.4 (28.2–35.1)NS
WHR0.82 (0.76–0.88)0.80 (0.74–0.87)P < 0.05
Glucose (mmol/l)5.1 (4.7–5.5)4.8 (4.4–4.9)P < 0.05
Insulin (pmol/l)70.0 (54.5–94.5)61.0 (43.5–83.0)NS
HOMA-IR2.2 (2.0–3.0)1.6 (1.3–2.2)P < 0.05
Cholesterol (mmol/l)4.9 (4.1–5.3)5.0 (4.1–5.4)NS
Triglycerides (mmol/l)1.0 (0.8–1.7)1.2 (1.0–1.9)NS
Testosterone (nmol/l)1.8 (1.5–2.5)1.3 (1.1–1.8)P < 0.05
Androstenedione (nmol/l)3.0 (2.3–3.8)2.8 (2.2–3.6)NS
DHEA-S (μmol/l)4.3 (2.7–5.6)5.4 (3.6–6.7)NS
SHBG (nmol/l)27.0 (20.5–41.0)29.0 (21.5–46.5)NS
FAI6.6 (4.6–9.7)5.3 (3.1–6.6)NS
SBP (mmHg)125.0 (120.0–130.0)120.0 (120.0–127.5)NS
DBP (mmHg)80.0 (75.0–80.0)75.0 (75.0–80.0)NS
IMT (mm)0.53 (0.48–0.58)0.47 (0.41–0.53)P < 0.05
hs-CRP (mg/l)3.3 (2.4–5.5)3.1 (2.0–6.2)NS
Omentin-1 (ng/ml)23.7 (20.0–27.9)59.2 (52.1–60.6)P < 0.01
  • Data are median (interquartile range). Group comparison by Mann–Whitney U test. Free androgen index (FAI) = T (nmol/l)/SHBG (nmol/l) × 100. NS = not significant; DHEA-S, dehydroepiandrosterone-sulfate; SHBG, sex hormone–binding globulin; SBP, systolic blood pressure; DBP, diastolic blood pressure.